Cocrystal Pharma Inc (COCP)

$2.35

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $2.35
    $2.45
    $2.35
    downward going graph

    0.0%

    Downside

    Day's Volatility :4.0%

    Upside

    4.0%

    downward going graph
  • $1.33
    $3.29
    $2.35
    downward going graph

    43.4%

    Downside

    52 Weeks Volatility :59.57%

    Upside

    28.57%

    downward going graph

Returns

PeriodCocrystal Pharma IncIndex (Russel 2000)
3 Months
54.61%
0.0%
6 Months
53.59%
0.0%
1 Year
-12.64%
0.0%
3 Years
-82.82%
-20.8%

Highlights

Market Capitalization
24.1M
Book Value
$2.22
Earnings Per Share (EPS)
-1.62
PEG Ratio
0.0
Wall Street Target Price
10.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-39.23%
Return On Equity TTM
-58.52%
Revenue TTM
510.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
26.900000000000002%
Gross Profit TTM
-8.8M
EBITDA
-20.0M
Diluted Eps TTM
-1.62
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.9
EPS Estimate Next Year
-1.98
EPS Estimate Current Quarter
-0.54
EPS Estimate Next Quarter
-0.56

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Cocrystal Pharma Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 325.53%

Current $2.35
Target $10.00

Technicals Summary

Sell

Neutral

Buy

Cocrystal Pharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cocrystal Pharma Inc
Cocrystal Pharma Inc
-11.65%
53.59%
-12.64%
-82.82%
-90.93%
Moderna, Inc.
Moderna, Inc.
-9.19%
21.5%
-4.18%
-62.27%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.99%
12.81%
44.78%
82.21%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-7.34%
24.69%
58.81%
196.23%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.88%
11.69%
35.62%
150.46%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cocrystal Pharma Inc
Cocrystal Pharma Inc
NA
NA
0.0
-1.9
-0.59
-0.39
NA
2.22
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cocrystal Pharma Inc
Cocrystal Pharma Inc
Buy
$24.1M
-90.93%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Cocrystal Pharma Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.8% return, outperforming this stock by 71.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 196.2% return, outperforming this stock by 279.0%

Institutional Holdings

  • Vanguard Group Inc

    2.71%
  • Renaissance Technologies Corp

    1.24%
  • BlackRock Inc

    0.72%
  • Geode Capital Management, LLC

    0.59%
  • Morgan Stanley - Brokerage Accounts

    0.58%
  • Susquehanna International Group, LLP

    0.51%

Company Information

cocrystal (otcqb:cocp) is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. cocrystal employs unique technologies and nobel prize winning expertise to create first- and best-in-class antiviral drugs. these technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. the company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. cocrystal has previously received strategic investments from teva pharmaceuticals, opko health (opk), dr. raymond schinazi, brace pharmaceutical, llc, and the frost group.

Organization
Cocrystal Pharma Inc
Employees
12
CEO
Dr. Roger D. Kornberg Ph.D.
Industry
Health Technology

FAQs